文章摘要
Jin Lü, Xiufeng Cao.[J].南京医科大学学报,2008,28(5):269~272
Dosimetry for 125I radioactive seed implantation therapy for hepatocellular carcinoma
投稿时间:2008-08-26  
DOI:10.7655
中文关键词: 
英文关键词: carcinoma, hepatocellular/radiotherapy  brachytherapy  radioactive seeds  125I
基金项目:
作者单位
Jin Lü Oncology Center, the Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, Jiangsu Province, China 
Xiufeng Cao  
摘要点击次数: 1152
全文下载次数: 1453
中文摘要:
      
英文摘要:
      Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious. In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially 125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local “conformal radiotherapy” and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn′t yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for 125I interstitial implantation brachytherapy for HCC.
查看全文   查看/发表评论  下载PDF阅读器
关闭